Key Metrics
18.4
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
>= 25
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.93
5-Year SI
5-year SI
- 0.93 2-year SI
- 0.93 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Genetics
SJR
- Q1 Genetics
- Q1 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
3.98
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
8 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
1%
4 to 6 months
25%
7 to 9 months
48%
Above 9 months
26%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
Scopus -
DOAJ -
SJR
Topics Covered
- Hepatocellular carcinoma
- Virus
- Mitochondrial biogenesis
- Tumor microenvironment
- Lung cancer
- Reactive oxygen species
- Neuroendocrine tumors
- Gallbladder
- Disease severity
- Autophagy
- Tyrosine hydroxylase
- Immunotherapy
- Central nervous system
- Peroxisome
- K562 cells
- Tumor growth
- Interferon
- Colorectal cancer
- Clinical trial
- Dependent manner
Journal Specifications
| Overview | |
| Publisher | SPRINGERNATURE |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2690 | USD 3190 | GBP 2390 |
| Publication Time | 5 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Sichuan University |
| Frequency | Continuous publication |
| Publication Start Year | 2016 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Other charges | Visit website |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 5 |
| Article Processing Charges | EUR 2690 | USD 3190 | GBP 2390 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY |
| OA statement | Visit website |
Planning to publish in Signal Transduction and Targeted Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer
- 9 Dec 24
- Signal Transduction and Targeted Therapy
-
Full paper
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
- 9 Dec 24
- Signal Transduction and Targeted Therapy
-
Full paper
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial
- 9 Dec 24
- Signal Transduction and Targeted Therapy
-
Full paper
Cellular pathophysiology of Duchenne muscular dystrophy: insights from a novel rhesus macaque model
- 7 Dec 24
- Signal Transduction and Targeted Therapy
-
Full paper
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
- 6 Dec 24
- Signal Transduction and Targeted Therapy
-
Full paper
Neutrophil diversity and function in health and disease
- 6 Dec 24
- Signal Transduction and Targeted Therapy
Scite analysis
Powered by scite_
2k articles received 84.8k citations see all
- 1,801 Supporting
- 82,248 Mentioning
- 128 Contrasting
Editorial notices
- 2 Retractions
- 0 Withdrawals
- 48 Corrections
- 39 Errata
- 0 Expression of Concern
FAQs
How long has Signal Transduction and Targeted Therapy been actively publishing?
Signal Transduction and Targeted Therapy has been in operation since 2016 till date.
What is the publishing frequency of Signal Transduction and Targeted Therapy ?
Signal Transduction and Targeted Therapy published with a Continuous publication frequency.
How many articles did Signal Transduction and Targeted Therapy publish last years ?
In 2023, Signal Transduction and Targeted Therapy published 467 articles.
What is the eISSN & pISSN for Signal Transduction and Targeted Therapy ?
For Signal Transduction and Targeted Therapy,eISSN is 2059-3635 and pISSN is2095-9907.
What is Citescore for Signal Transduction and Targeted Therapy ?
Citescore for Signal Transduction and Targeted Therapy is 18.4.
What is SNIP score for Signal Transduction and Targeted Therapy ?
SNIP score for Signal Transduction and Targeted Therapy is 3.98.
What is the SJR for Signal Transduction and Targeted Therapy ?
SJR for Signal Transduction and Targeted Therapy is Q1.
Who is the publisher of Signal Transduction and Targeted Therapy ?
SPRINGERNATURE is the publisher of Signal Transduction and Targeted Therapy.